A groundbreaking blood test has been developed that has the potential to revolutionize cancer diagnosis within the NHS, according to scientists. The Galleri test, designed to detect over 50 types of cancer, demonstrated an accuracy rate of 62% in identifying individuals with the disease and accurately ruling out cancer in 99.6% of those without it.
The promising results from the US trial coincide with ongoing trials within the NHS for this innovative multi-cancer blood test, which has been hailed as a game-changer by medical experts. Sir Harpal Kumar, a key figure in the development of Galleri, expressed great enthusiasm about the test’s potential to significantly enhance cancer outcomes by detecting a higher number of cancers at earlier stages.
Traditionally, the NHS offers screening tests for only four types of cancer, involving scans or invasive biopsies. The introduction of multi-cancer early detection tests like Galleri could transform the approach to cancer screening by enabling the simultaneous detection of numerous cancers from a single blood sample.
The Galleri test, which can be administered annually, identifies the unique DNA signatures of various cancers present in the bloodstream, offering early indications of the disease. Notably, the US trial involving 23,000 asymptomatic participants revealed that 61.6% of individuals with a “cancer signal” detected in their blood were later diagnosed with cancer.
While acknowledging the test’s imperfections, Prof. Anna Schuh from Oxford University highlighted the potential of Galleri to save time and resources by accurately pinpointing the organ or tissue of cancer origin in 92% of cases. The study also found that a significant portion of the newly detected cancers were at early stages, potentially leading to improved outcomes for patients.
The data from these trials is being presented at the European Society for Medical Oncology (ESMO) Congress in Berlin, emphasizing the growing interest and potential impact of such advanced cancer screening technologies. Leaders in the field, including Professor Clare Turnbull, are calling for further research to determine the effectiveness of tests like Galleri in reducing cancer-related deaths.
Overall, the development and implementation of multi-cancer blood tests like Galleri hold great promise for revolutionizing cancer detection and improving patient outcomes within the healthcare system.